HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reaffirmed a Buy rating on LifeMD (NASDAQ: LFMD) and increased the price target from $10 to $12, indicating a positive outlook on the company's stock.
January 11, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD's stock may see a positive short term impact due to the Buy rating reaffirmation and raised price target from $10 to $12 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by HC Wainwright & Co. suggests a strong conviction in LifeMD's growth prospects, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100